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Chikungunya virus (CHIKV) is an emerging mosquito borne alphavirus indigenous to tropical Africa and Asia, which has caused massive outbreaks of endemic and epidemic fever for at least half a century. Unfortunately, recent evidence suggests that CHIKV, which infects humans via the mosquito vector Aedes species, can be transmitted by other carriers, raising concern of continued pathogen spread outside of its original host. CHIKV is no longer confined to the developing world as it has begun to branch into the boundaries of neighboring regions. As a result, the NIAID has designated CHIKV as a Category C pathogen alongside the influenza and SARS-CoV viruses. Despite the emergence of CHIKV, no licensed vaccines or therapeutics are currently available for preventing or treating CHIKV infection. Realization of the potential severity of CHIKV-induced disease is exigent; for example, if used as a biological weapon, the world economy could be severely crippled. If enough members of the armed forces were to become infected during a military deployment, a military operation could be significantly affected. Efforts to monitor the disease will only provide minimal warning in a global society. Accordingly, steps should be taken to prevent the morbidity and mortality associated with a CHIKV pandemic. In an effort to address this important need, we isolated a new CHIKV virus from an acutely infected human patient and developed a defined viral challenge stock in mice and neutralization assay. We then constructed a synthetic DNA vaccine that expresses the component of the CHIKV envelope glycoprotein. Following electroporation (EP) immunization of the vaccine, we observed induction of robust antigen-specific cellular and humoral immune responses individually capable of providing protection against CHIKV challenge in mice. Furthermore, vaccine studies in Rhesus Macaques demonstrated strong neutralizing antibody (Nab) responses which mimicked those induced in convalescent human patient sera. These data suggest a protective role for neutralizing antibodies against CHIKV disease and support further study of envelope-based CHIKV DNA vaccines.
